Introduction
Restenosis is a frequent complication after percutaneous transluminal (coronary) angioplasty (PT(C)A), leading to the obstruction of dilated arteries in 20-30% of patients within 6 months after the procedure. 1 Although drugeluting stents have alleviated this problem, there is a clear need to develop other treatment strategies. Local gene transfer to vascular wall could offer an alternative approach for the prevention of restenosis after PT(C)A and coronary stenting.
Members of the vascular endothelial growth factor (VEGF) family are angiogenic growth factors that also have vasculoprotective effects. 2, 3 They stimulate endothelial cell (EC) proliferation and act as endothelial survival factors. 2, 3 Adenoviral gene therapy against restenosis with VEGF-C has already been shown to be effective in a preclinical study 4 and clinical studies using intra-arterial gene transfer with VEGF-A have been safe and feasible. [5] [6] [7] VEGF-D is a novel member of the VEGF family that is synthetised as a prepropeptide and proteolytically processed to the biologically active form that binds to two tyrosine-kinase receptors VEGFR-2 (Flk-1/KDR) and VEGFR-3 (Flt-4). 8, 9 In human atherosclerosis VEGF-D is present throughout the lesion development, but its amounts are reduced in complicated lesions. 10 Furthermore, in complicated lesions most of the VEGF-D appears to be intracellular and not effectively processed into its extracellular mature form. 10 Thus, gene transfer using the secreted proteolytically processed biologically active form of VEGF-D, VEGF-D DNDC , could have beneficial effects on the treatment of postangioplasty restenosis.
In this study, we analyzed the effect of intravascular adenovirus-mediated VEGF-D DNDC gene transfer on neointimal formation in a rabbit balloon denudation model. It was found that adenoviral (Ad)VEGF-D DNDC reduced neointima formation and macrophage accumulation in the balloon-denuded rabbit aorta in a nitric oxide (NO)-dependent fashion.
Results

VEGF-D DNDC protein induces endothelial tube formation in matrigel
The capability of VEGF-D DNDC secreted from transduced vascular smooth muscle cells (SMCs) to induce EC tube formation was tested in vitro in matrigel (Figure 1 ).
In VEGF-D DNDC -treated wells the endothelial tube formation was significantly enhanced as compared to LacZ controls (P ¼ 0.017).
The efficiency of intravascular adenovirus-mediated gene transfer
Gene transfer efficiency was determined by analyzing bgalactosidase activity with X-gal staining. Transduced cells were located in neointima and media near to the internal elastic lamina (IEL) (Figure 2a and b) . At 6 days time point, the gene transfer efficiency was 1.9171.32% in intima and 0.2170.08% in media (Figure 2a) . At 2 weeks after the gene transfer, 0.3070.09% of the intimal cells and 0.1570.03% of the medial cells were positive for X-gal staining (Figure 2b ). Only sporadic X-galpositive cells were found at 4 weeks time point (data not shown). The transduced VEGF-D DNDC mRNA was readily detectable in the target area with RT-PCR at each time point (Figure 2c ).
AdVEGF-D DNDC gene transfer reduces neointima formation
Balloon denudation of the rabbit aorta results in intimal thickening and SMC proliferation. The intima/media ratios (I/M) were determined from animals killed 6, 14 or 28 days after the gene transfer. At 2 weeks after the gene transfer, the AdVEGF-D DNDC group showed a 52% decrease (P ¼ 0.039) in I/M as compared to the AdLacZ control group (Figures 3 and 4a and b) . No differences were found in I/M between the study groups 6 days and 4 weeks after the gene transfer ( Figure 3 Figure 4c and d). The damage to the IEL was equal in each time point, showing that the initial injury to the aorta did not differ DNDC reduces neointima formation in balloondenuded rabbit aorta 14 days after gene transfer. At 6 or 28 days after the gene transfer, there were no statistically significant differences between the study groups. *Po0.05.
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between the study groups ( Table 1 ). There were no significant differences in endothelial regrowth (Table 1 ; Figure 4e and f) and in the number of proliferating cells between the study groups (Table 1) . Also, no differences in monocyte chemoattractant protein-1 (MCP-1) expression in vessel wall were detected (Figure 4g and h).
Therapeutic effect on neointima formation is blocked by the inhibition of NO production
The therapeutic mechanism of AdVEGF-D DNDC gene transfer was studied by inhibiting NO production with NO synthase inhibitor, L-nitroarginine methyl ester (L-NAME). L-NAME blocked the reduction in neointimal 
VEGF-D gene therapy for restenosis
J Rutanen et al growth completely 2 weeks after the gene transfer ( Figure 5 ). There were no differences in macrophage influx, damage to the IEL, endothelial regrowth or proliferating cells between the study groups (data not shown).
Catheter-mediated gene transfer with adenoviral vector causes transduction of ectopic organs
Intravascular adenoviral gene transfer results in biodistribution of the vector. 11 Positive cells were found in all tested organs with X-gal staining at 6 days time point: lung, liver, spleen, kidney and testis ( Figure 6 ). Spleen and liver were the most prominently transducted organs. Consequently, a transient increase was detected in serum levels of the transduced human VEGF-D DNDC after adenoviral gene transfer (Figure 7a ). Although we used a growth factor which is associated with strong angiogenesis and edema, 12,13 such effects were not detected in ectopic organs (data not shown). No significant differences were found in serum values for C-reactive protein (CRP), Creatinine (Crea), aspartate aminotransferase (AST), alkaline phosphatase (AP) and lactate dehydrogenase (LDH) (Figure 7b-f) . NS -not significant.
Figure 5
The therapeutic effect of AdVEGF-D DNDC gene transfer on neointima formation at 2 weeks time point is completely blocked with daily oral administration of NO synthase inhibitor L-NAME. *Po0.05. NS ¼ not significant. 
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Discussion
Intra-arterial manipulation damages the endothelium and predisposes vessels to inflammatory reactions, thrombus formation and SMC proliferation, which lead to neointima formation and restenosis.
14 In previous studies, some members of the VEGF family have shown potential for the prevention of restenosis. 4, 15 VEGF-D is constitutively expressed in normal human arteries and early-stage atherosclerosis, but the expression is decreased and its biological processing to the mature form is disturbed in connective tissue-rich atherosclerotic lesions. 10 Consequently, the vasculoprotective effects of VEGF-D may be decreased in end-stage atherosclerotic lesions that are candidates for PT(C)A. In this study, we tested the hypothesis that intra-arterial gene transfer using the mature form of VEGF-D could be protective and prevent restenosis.
It was found that AdVEGF-D DNDC gene transfer reduced neointima formation in balloon-denuded rabbit aorta via NO-dependent mechanisms. VEGF-D signals through two tyrosine kinase receptors, VEGFR-2 and VEGFR-3. 8 The mature form of VEGF-D DNDC used in this study binds effectively to VEGFR-2, which induces NO production from endothelium. 12, 16 Since the therapeutic effects of intravascular AdVEGF-D DNDC gene transfer were completely blocked by L-NAME, the effects are mediated through NO. The mechanisms behind the NO-mediated effect are probably a direct inhibition of vascular SMC proliferation 17, 18 and NO-induced vascular relaxation. 19 Importantly, our study showed reduced macrophage number in the vessel wall 6 days after the intravascular AdVEGF-D DNDC gene transfer. Thus, an additional mechanism behind the therapeutic effect may be the NO-dependent modulation of cytokine activities, followed by the reduced macrophage influx into the vessel wall after the AdVEGF-D DNDC gene transfer. Inflammatory response after angioplasty and stenting is one of the key elements that lead to neointimal hyperplasia and restenosis. [20] [21] [22] [23] NO is a known inhibitor of several cytokine-mediated processes that participate in the inflammatory response leading to restenosis. NO regulates MCP-1 in endothelial and SMCs. 24, 25 Vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) are also regulated by NO. 26, 27 Elevated MCP-1 and VCAM-1 levels have been documented in patients with restenosis. 28, 29 However, in this study, we could not detect any changes in MCP-1 in the vessel wall after AdVEGF-D DNDC gene transfer using immunohistochemical stainings.
We achieved 1.9171.32% gene transfer efficiency in the intima at 6 days time point. At 2 weeks after the gene transfer, the amount of X-gal-positive cells was considerably lower and only sporadic positive cells were detected at 4 weeks time point. This is probably due to the transient nature of adenoviral gene transfer. In human arteries, the gene transfer efficiency in atherosclerotic arteries is 2-5%. 30 The dissection lines caused by the angioplasty balloon in human arteries may allow transduction of deeper layers of the artery. 30 Thus, therapeutic effects could be achieved by using adenovirus encoding secreted soluble gene products, such as VEGF-D DNDC . It is possible that the use of needleinjection catheters might lead to better transduction efficiencies. However, their safety in the clinical setting remains unclear. The therapeutic effect with the adenoviral vector was no longer detectable 4 weeks after the gene transfer and a vector that provides a longer expression time may be needed to achieve sustained prevention of restenosis in humans. Also, combining adenoviral gene transfer with an agent that has an inhibitory effect on cell proliferation may provide more sustained effects. 31 No major side effects were found in the study although catheter-mediated intra-arterial gene transfer led to a biodistribution of the adenoviral vector to ectopic organs and an increase in serum level of the transduced VEGF-D DNDC . No detectable changes were found in the serum levels of CRP, Crea, LDH, AST or AP in AdVEGF-D DNDC -or AdLacZ-treated animals. VEGF-D DNDC is a powerful angiogenic growth factor that induces strong 
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J Rutanen et al angiogenic effects even in nonischemic skeletal muscle and myocardium. 12, 13 However, there were no signs of unwanted angiogenesis in any of the studied organs, suggesting that local growth factor levels in ectopic tissues remained low. Our earlier clinical trials show that intra-arterial gene transfer with a similar adenoviral dose is safe and well tolerated. [5] [6] [7] 30 Due to the size of the target artery, we used the same viral dose in rabbits that was used in clinical trials. Thus, the biodistribution of the same effective dose is probably significantly lower in humans than in rabbits. 32 In conclusion, intra-arterial adenovirus-mediated VEGF-D DNDC gene transfer reduced neointimal thickening in balloon-denuded rabbit aortas at 2 weeks. The effect was associated with a reduced macrophage influx into the vessel wall and was mediated by NO. Thus, gene transfer of the mature form of VEGF-D DNDC may be useful for the prevention of neointimal hyperplasia after vascular manipulations.
Materials and methods
Adenovirus constructs
Adenovirus vectors containing the human VEGF-D DNDC and nuclear-targeted LacZ were produced as described. 4 The viruses were analyzed for the absence of microbial contaminants, replication-competent adenoviruses and lipopolysaccharide (Limulus assay; Sigma).
30,33
EC tube formation assay
Rabbit aortic smooth muscle cells (RAASMC) were incubated for 30 min in serum-free medium containing VEGF-D DNDC or LacZ adenoviruses at a multiplicity of infection (MOI) of 1000. The ability of VEGF-D DNDC to induce human EC (EA hy926) tube formation was thereafter analyzed with the conditioned medium in matrigel. 4, 34 Tube formation was measured by counting the number of connected cells per well (n ¼ 4 wells in both groups).
Animal experiments
New Zealand White (NZW) rabbits (n ¼ 4-9 in each group) were on 0.25% cholesterol diet for 2 weeks before balloon denudation. The whole aorta was denuded twice by using a 3.0 F arterial embolectomy catheter (Sorin Biomedical, CA, USA). 4 After 3 days, the gene transfer was performed using a 3.5 F Dispatcht local drug delivery catheter (Boston Scientific, MA, USA). Under fluoroscopical control, the catheter was positioned caudal to the left renal artery in a segment free of side branches and the gene transfer was performed at 6 ATM pressure for 10 min 2.0 Â 10 12 viral particles (vp) of AdLacZ or AdVEGF-D DNDC were used in a total volume of 2 ml of 0.9% NaCl. Animals were killed and the samples were collected 6, 14 or 28 days after the gene transfer. To study the role of NO in the downstream signaling of VEGF-D DNDC , two groups were fed with NO synthase inhibitor L-NAME (N-5751, Sigma, 100 mg/kg/ day) and killed at 2 weeks time point. 35 The study protocol was approved by the Experimental Animal Committee of the University of Kuopio and it conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Histology
At 3 h before killing, animals were injected i.v. with 50 mg of BrdU dissolved in 40% ethanol. After killing, the transduced segment of aorta was removed, flushed gently with saline and divided into four equal parts. 4, 36 The proximal part was immersion-fixed in 4% paraformaldehyde/15% sucrose (pH 7.4) for 4 h, rinsed in 15% sucrose (pH 7.4) overnight and embedded in paraffin. The next part was fixed in 4% paraformaldehyde/ phosphate-buffered saline (PBS) (pH 7.4) for 10 min, rinsed in PBS, embedded in OCT compound (Miles) and stored at À701C. The third part was fixed in 70% ethanol overnight and embedded in paraffin. The distal part was snap frozen in liquid nitrogen and stored at À701C. Tissue samples from liver, lung, spleen, kidney and testis were collected for safety analyses.
Paraffin sections were used for the measurement of neointimal growth (hematoxylin-eosin (HE)) and for immunohistochemical analyses of SMCs (HHF35; DAKO, dilution 1:50), macrophages (RAM-11; DAKO, 1:50), endothelium (CD31; DAKO, 1:50) and MCP-1 (R&D Systems, AF-279-NA, 1:5). Controls for immunostainings included incubations with class-and speciesmatched immunoglobulins and incubations where primary antibodies were omitted. 4, 36 Evaluation of the gene transfer efficiency was carried out using X-gal staining of OCT-embedded tissue sections. 35 BrdU-positive cells were detected with an mAb (DAKO, 1:100) from ethanol-fixed paraffin sections. Morphometrical analyses were performed using analySIS s software (Soft Imaging System, Germany) with Olympus AX70 microscope (Olympus Optical, Japan). Measurements for histological parameters (I/M, intact endothelium, macrophage count, MCP-1, intact IEL and proliferating cells) were carried out by one observer from randomly selected multiple sections (4/rabbit) in a blinded manner. Intact endothelium was quantified from CD31-immunostained sections, macrophage count from RAM-11-stained sections and proliferating cells from BrdU-stained sections. I/M and intact IEL were analyzed from HE-stained sections. MCP-1 expression was evaluated semiquantitatively from immunostained sections using the following criteria: no detectable staining (0); weak staining (1), meaning that less than 10% of the lesion area was positive for the studied signal; moderate staining (2), meaning that 10-50% of the area was positive for the studied signal; strong staining (3), meaning that more than 50% of the area was positive for the studied signal. 37 
RT-PCR
Expression of the transduced VEGF-D DNDC in arterial segments was confirmed with RT-PCR. Total RNA was extracted with Trizol Reagent (Gibco BRL) according to the manufacturer's instructions and treated with DNaseI (Promega, Madison, WI, USA) to remove any contaminating DNA. cDNA synthesis was performed with 1.5 mg of RNA in a volume of 15 ml using random hexamer primers. A volume of 5 ml aliquot of each cDNA sample was used for PCR. Primers for PCR amplification were as follows: forward: 5 0 -TTGCCAGCTCTACCAC CAG-3 0 and reverse: 5 0 -TTCATTGCAACAGCCACCAC-3 0 , resulting in a 292 bp product. PCR reaction mixtures consisted of 20 pmol of each primer, 0.2 mM dNTPs (Promega), 1.5 mM MgCl 2 , Dynazyme EXT PCR buffer VEGF-D gene therapy for restenosis J Rutanen et al and 1.5 U of Dynazyme EXT DNA polymerase (Finnzymes). PCR amplification was carried out using the following conditions: the first denaturation step at 951C for 10 min, followed by 40 cycles for 45 s at 951C, 45 s at 561C, 45 s at 721C with the final step at 721C for 15 min.
ELISA analyses and clinical chemistry
For quantitative measurement of the transduced human VEGF-D DNDC protein in serum, ELISA assays were performed according to the manufacturer's instructions (cat no: DVED00; Quantikine, R&D Systems). CRP, Crea, AST, AP and LDH were measured from serum using standard assays at the Department of Clinical Chemistry, Kuopio University Hospital.
Statistical analyses
ANOVA, followed by a modified t-test was used to evaluate statistical significance (Po0.05). Semiquantitative results from MCP-1 immunostainings were analyzed by Kruskal-Wallis test, followed by multiple comparisons using Mann-Whitney U test. Mean7s.e.m. of each measurement is presented.
